Travere Therapeutics Inc TVTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:39 AM EDT
25.63quote price arrow up+0.41 (+1.63%)
Volume
31,052
52 week range
14.12 - 33.09

...

Loading . . .
  • Open24.97
  • Day High25.63
  • Day Low24.00
  • Prev Close25.22
  • 52 Week High33.09
  • 52 Week High Date02/02/21
  • 52 Week Low14.12
  • 52 Week Low Date05/01/20

Key Stats

  • Market Cap1.549B
  • Shares Out60.44M
  • 10 Day Average Volume0.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.67
  • YTD % Change-6.73

KEY STATS

  • Open24.97
  • Day High25.63
  • Day Low24.00
  • Prev Close25.22
  • 52 Week High33.09
  • 52 Week High Date02/02/21
  • 52 Week Low14.12
  • 52 Week Low Date05/01/20
  • Market Cap1.549B
  • Shares Out60.44M
  • 10 Day Average Volume0.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.67
  • YTD % Change-6.73

RATIOS/PROFITABILITY

  • EPS (TTM)-3.82
  • P/E (TTM)-6.71
  • Fwd P/E (NTM)-16.96
  • EBITDA (MRQ)-50.798M
  • ROE (MRQ)-87.32%
  • Revenue (MRQ)198.32M
  • Gross Margin (MRQ)96.91%
  • Net Margin (MRQ)-95.19%
  • Debt To Equity (MRQ)101.95%

EVENTS

  • Earnings Date05/07/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Travere Therapeutics Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Travere Therapeutics Inc., formerly Retrophin Inc., is a biopharmaceutical company. The Company specializing in identifying, developing and delivering therapies to people living with rare disease. It's pipeline includes sparsentan (RE-021), a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Sparsentan is an investigational product candidate with a dual mechanism of action, selective endothelin receptor...
Gary Lyons
Chairman
Eric Dube Ph.D.
President
Laura Clague CPA
Chief Financial Officer
Address
3611 Valley Centre Dr, Suite 300
San Diego, CA
92130-3330
United States

Top Peers

SYMBOLLASTCHG%CHG
RGNX
Regenxbio Inc
33.17-0.11-0.33%
TBIO
Translate Bio Inc
20.08+0.29+1.49%
CARA
Cara Therapeutics Inc
27.84+0.35+1.27%
IMGN
ImmunoGen Inc
7.41+0.09+1.23%
FGEN
FibroGen Inc
20.34-0.01-0.05%